Skip to main content

Table 2 18F-FDG accumulation in the mainly involved organs and tissues in patients with AOSD compared with healthy controls

From: Total metabolic lesion volume of lymph nodes measured by 18F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still’s disease

  N (%) SUVmax in patients with AOSD Bilateral (n) SUVmax in healthy controls p
Bone marrow 5.10 (4.25–6.10) 3.76 (3.00–4.15) < 0.001
Spleen 3.70 (3.05–4.35) 2.28 (2.06–2.56) < 0.001
Liver 3.20 (2.80–3.60) 3.26 (2.88–3.58) 0.672
Lymph nodes# 38 (66.67) 5.55 (4.05–8.68)
 Cervical LN 30 (52.63) 5.15 (3.92–7.85) 26/30
 Axillary LN 27 (47.37) 4.70 (2.70–6.00) 25/27
 Mediastinum LN 19 (33.33) 5.30 (3.70–8.90)
 Pelvic LN 16 (28.07) 6.45 (4.68–8.52)
 Retroperitoneal LN 14 (24.56) 5.60 (3.15–7.72)
 Inguinal LN 13 (22.81) 4.20 (2.65–5.20) 10/13
 Abdominal LN 8 (14.04) 6.60 (5.25–7.70)
  1. Data are presented in the form of median (Q1–Q3) as continuous variable
  2. SUV standardized uptake value
  3. #This was calculated from the patients with hypermetabolic lymph nodes (n = 38). SUVmax was the maximum SUV of the regional lymph node